SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bharat Parenterals’ arm signs deal with two Global Complex Generic marketing companies

13 Mar 2024 Evaluate

Bharat Parenterals’ subsidiary Innoxel Lifesciences has signed a deal to out license seven complex molecules including two, 505(b) 2 products with two Global Complex Generic marketing companies. According to agreement, Innoxel Lifesciences will receive cumulative milestone payments of Rs 31 crore over the period of next three years (Rs 10.3 crore every year). Primary countries for Marketing will be United States and some of the European countries.

Innoxel Lifesciences has developed total twenty-two complex generic molecules, including seven 505(b) 2. Additional sixteen molecules are in pipeline and likely to be developed over the next two years. Innoxel Lifesciences has a state-of-the-art manufacturing facility with SKID based technology in Vadodara to manufacture these drugs. On successful filing and approval of these molecules, company will manufacture drugs on contract manufacturing basis and will also receive Profit Share income after commercialisation in the future.

Innoxel Lifesciences was incorporated in the year 2021 with the vision of developing and manufacturing of highly complex generic molecules, including 505(b) 2 for the regulated markets, mainly the United States and select Western European countries.

Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.

Bharat Parenterals Share Price

1213.10 32.30 (2.74%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×